JP5478894B2 - キナゾリン誘導体、その調製法および使用法 - Google Patents

キナゾリン誘導体、その調製法および使用法 Download PDF

Info

Publication number
JP5478894B2
JP5478894B2 JP2008550608A JP2008550608A JP5478894B2 JP 5478894 B2 JP5478894 B2 JP 5478894B2 JP 2008550608 A JP2008550608 A JP 2008550608A JP 2008550608 A JP2008550608 A JP 2008550608A JP 5478894 B2 JP5478894 B2 JP 5478894B2
Authority
JP
Japan
Prior art keywords
chloro
fluorobenzyloxy
phenylamino
quinazoline
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008550608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525956A5 (enExample
JP2009525956A (ja
Inventor
郭建▲輝▼
王猛
姜勇
▲張▼▲曉▼芳
Original Assignee
上▲海▼艾力斯医▲藥▼科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上▲海▼艾力斯医▲藥▼科技有限公司 filed Critical 上▲海▼艾力斯医▲藥▼科技有限公司
Publication of JP2009525956A publication Critical patent/JP2009525956A/ja
Publication of JP2009525956A5 publication Critical patent/JP2009525956A5/ja
Application granted granted Critical
Publication of JP5478894B2 publication Critical patent/JP5478894B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008550608A 2006-01-20 2006-10-20 キナゾリン誘導体、その調製法および使用法 Active JP5478894B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200610023526.7 2006-01-20
CNA2006100235267A CN101003514A (zh) 2006-01-20 2006-01-20 喹唑啉衍生物、其制备方法及用途
PCT/CN2006/002786 WO2007082434A1 (en) 2006-01-20 2006-10-20 Quinazoline derivatives,preparation methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012173258A Division JP2012214502A (ja) 2006-01-20 2012-08-03 キナゾリン誘導体、その調製法および使用法

Publications (3)

Publication Number Publication Date
JP2009525956A JP2009525956A (ja) 2009-07-16
JP2009525956A5 JP2009525956A5 (enExample) 2012-02-23
JP5478894B2 true JP5478894B2 (ja) 2014-04-23

Family

ID=38287245

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008550608A Active JP5478894B2 (ja) 2006-01-20 2006-10-20 キナゾリン誘導体、その調製法および使用法
JP2012173258A Withdrawn JP2012214502A (ja) 2006-01-20 2012-08-03 キナゾリン誘導体、その調製法および使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012173258A Withdrawn JP2012214502A (ja) 2006-01-20 2012-08-03 キナゾリン誘導体、その調製法および使用法

Country Status (5)

Country Link
US (2) US8044063B2 (enExample)
EP (2) EP2248806B1 (enExample)
JP (2) JP5478894B2 (enExample)
CN (2) CN101003514A (enExample)
WO (1) WO2007082434A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CN101245050A (zh) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
CN101347433B (zh) * 2007-07-20 2012-05-02 江苏艾力斯生物医药有限公司 4-苯胺喹唑啉衍生物的制药用途
CN101357905B (zh) * 2007-08-01 2012-06-20 江苏艾力斯生物医药有限公司 4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-6-取代胺基-喹唑啉衍生物的制备方法
CN101544609A (zh) 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的结晶形式
AU2013231084B2 (en) * 2008-03-25 2015-06-18 Shanghai Allist Pharmaceuticals Co., Ltd. The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
BRPI1011505A2 (pt) 2009-03-11 2016-03-22 Auckland Uniservices Ltd formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
CN101899011B (zh) * 2009-05-26 2013-01-16 北京大学 氨基二硫代甲酸酯类化合物、其制备方法和应用
CN102574846B (zh) 2009-09-02 2014-12-03 奥克兰联合服务有限公司 激酶抑制剂、其前药形式及它们在治疗中的用途
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
CN102153544B (zh) * 2010-02-12 2015-04-29 上海阳帆医药科技有限公司 一类酪氨酸激酶抑制剂的制备及用途
CN101857617A (zh) * 2010-04-28 2010-10-13 中国海洋大学 喹唑啉类糖衍生物及其制备方法和应用
CN101857618B (zh) * 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
JP6437820B2 (ja) 2011-07-27 2018-12-12 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
CN103304572A (zh) * 2012-03-09 2013-09-18 上海医药集团股份有限公司 一类3-氰基喹啉类化合物及其药用组合物和应用
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
CN102702116B (zh) * 2012-06-13 2014-12-31 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
CN102924387B (zh) * 2012-06-13 2015-07-01 黄唯燕 4-(3-氯-4-甲氧基苯胺基)-6-(3,4-取代苯基)喹唑啉及盐和制法与应用
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
KR20200091954A (ko) * 2014-12-15 2020-07-31 더 리젠츠 오브 더 유니버시티 오브 미시간 Egfr 및 pi3k의 소분자 억제제
EP3272746B1 (en) 2015-03-20 2019-12-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing same
CN105384745A (zh) * 2015-07-27 2016-03-09 北京师范大学 冠醚环状的喹唑啉类化合物及其制备方法和在制备肿瘤治疗与显像药物中的应用
CN109952290B (zh) * 2016-11-17 2022-05-03 广东众生药业股份有限公司 Fgfr4抑制剂及其制备方法和应用
EP4194443A4 (en) * 2020-08-10 2024-10-09 Abbisko Therapeutics Co., Ltd. Efgr inhibitor, preparation method therefor, and application thereof
US20240239764A1 (en) 2020-12-22 2024-07-18 Mekanistic Therapeutics Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU5391099A (en) * 1998-07-30 2000-02-21 American Home Products Corporation Substituted quinazoline derivatives
AU5783300A (en) 1999-07-09 2001-01-30 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
CZ20021009A3 (cs) * 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
BR0014133A (pt) * 1999-09-21 2002-06-11 Astrazeneca Ab Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US20070123537A1 (en) * 2003-10-06 2007-05-31 Gpc Biotech Ag Quinazoline derivatives for the treatment of herpesviral infections
JP2007510667A (ja) * 2003-11-07 2007-04-26 スミスクライン ビーチャム （コーク） リミテッド 癌の治療法
WO2005097134A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途

Also Published As

Publication number Publication date
EP2248806A2 (en) 2010-11-10
JP2012214502A (ja) 2012-11-08
EP2248806B1 (en) 2013-04-24
CN101003514A (zh) 2007-07-25
CN101103005B (zh) 2011-05-04
US20080300248A1 (en) 2008-12-04
EP1990337A1 (en) 2008-11-12
US8044063B2 (en) 2011-10-25
US20110245246A1 (en) 2011-10-06
CN101103005A (zh) 2008-01-09
EP1990337B1 (en) 2013-05-08
WO2007082434A1 (en) 2007-07-26
EP2248806A3 (en) 2011-02-23
US8309563B2 (en) 2012-11-13
JP2009525956A (ja) 2009-07-16
EP1990337A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
JP5478894B2 (ja) キナゾリン誘導体、その調製法および使用法
JP6437820B2 (ja) キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
KR101579148B1 (ko) 4-페닐아미노 퀴나졸린 유도체의 다형체, 그 제조 방법 및 용도
WO2013017073A1 (zh) 喹唑啉衍生物、含该衍生物的组合物及所述衍生物的制药用途
AU2015303724B2 (en) Quinazoline derivative
JP2009242240A (ja) 含ホウ素キナゾリン誘導体
CA3093323C (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
JP5504460B2 (ja) ４−フェニルアミノキナゾリン誘導体の塩形態
JP2012526054A (ja) 複素環置換のジフェニル尿素類誘導体及びその用途
WO2009012702A1 (fr) Utilisation d'un dérivé de 4-aniline quinazoline pour la préparation de médicaments
MXPA05006582A (es) Complejos de e-2-metoxi -n-(3 -{4-[3 -metil-4 -(6-metilpiridin -3- iloxi) fenilamino] quinazolin -6-il} alil) acetamida, su procedimiento de produccion y uso.
CN112159392B (zh) 取代嘧啶化合物及其药物组合物和该化合物的用途
CN120081824A (zh) 一种Betti碱衍生物及其合成方法和应用
CN110078712A (zh) 一类含有氨基咪唑基化合物、其药物组合物和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110930

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140212

R150 Certificate of patent or registration of utility model

Ref document number: 5478894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250